Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2015

01-11-2015 | Research Article

SEMA6A is a prognostic biomarker in glioblastoma

Authors: Jiaxin Zhao, Haitao Tang, Hong Zhao, Wanli Che, Lei Zhang, Peng Liang

Published in: Tumor Biology | Issue 11/2015

Login to get access

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive tumors in the central nervous system. SEMA6A, the first identified class 6 semaphorin, is contributed to regulate vascular development and adult angiogenesis. However, the function of SEMA6A in GBM is still undefined. In the present study, we investigated the expression of SEMA6A protein in 200 GBM tissues using immunohistochemistry (IHC). SEMA6A expression was associated with time to progression (P = 0.001) and mean tumor diameter (P = 0.038). Kaplan–Meier analysis revealed that patients expressing high SEMA6A protein levels had a significantly longer overall survival (OS, P = 0.013) and progression-free survival (PFS, P = 0.005) compared to those with low SEMA6A expression level. Cox multivariate regression analysis confirmed that low SEMA6A expression was an independent unfavorable prognostic factors for PFS (HR, 1.896; 95 % CI, 1.147–2.768; P = 0.009) and OS (HR, 1.712; 95 % CI, 1.011–2.657; P = 0.012). Furthermore, in vitro experiments showed that SEMA6A could inhibit proliferation, migration, and invasion in different glioma cell lines. In conclusion, our findings indicated that SEMA6A may be a potential prognostic biomarker in the treatment of GBM.
Literature
1.
2.
Rousseau A, Mokhtari K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system—what has changed? Curr Opin Neurol. 2008;21:720–7.CrossRefPubMed
3.
Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60:166–93.CrossRefPubMedPubMedCentral
4.
Semaphorin Nomenclature Committee. Letter to the editor: unified nomenclature for the semaphorins/collapsins. Cell. 1999;97:551–2.CrossRef
5.
Pasterkamp RJ. Getting neural circuits into shape with semaphorins. Nat Rev Neurosci. 2012;13:605–18.CrossRefPubMed
6.
7.
Kumanogoh A, Kikutani H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol. 2013;13:802–14.CrossRefPubMed
8.
Martin-Satue M, Blanco J. Identification of semaphorin E gene expression in metastatic human lung adenocarcinoma cells by mRNA differential display. J Surg Oncol. 1999;72:18–23.CrossRefPubMed
9.
Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B‑CLL growth and survival. Blood. 2005;105:3042–50.CrossRefPubMed
10.
Hu B, Guo P, Bar-Joseph I, et al. Neuropilin‑1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene. 2007;26:5577–86.CrossRefPubMedPubMedCentral
11.
Hirota E, Yan L, Tsunoda T, et al. Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol. 2006;29:799–827.PubMed
12.
Zhou L, White FA, Lentz SI, et al. Cloning and expression of a novel murine semaphorin with structural similarity to insect semaphorin I. Mol Cell Neurosci. 1997;9:26–41.CrossRefPubMed
13.
Bron R, Vermeren M, Kokot N, et al. Boundary cap cells constrain spinal motor neuron somal migration at motor exit points by a semaphorin–plexin mechanism. Neural Dev. 2007;2:21.CrossRefPubMedPubMedCentral
14.
Little GE, López-Bendito G, Rünker AE, et al. Specificity and plasticity of thalamocortical connections in Sema6A mutant mice. PLoS Biol. 2009;7, e98.CrossRefPubMed
15.
Mauti O, Domanitskaya E, Andermatt I, et al. Semaphorin6A acts as a gate keeper between the central and the peripheral nervous system. Neural Dev. 2007;2:28.CrossRefPubMedPubMedCentral
16.
17.
Suto F, Tsuboi M, Kamiya H, et al. Interactions between plexin-A2, plexin-A4, and semaphorin 6A control lamina-restricted projection of hippocampal mossy fibers. Neuron. 2007;53:535–47.CrossRefPubMed
18.
Bernard F, Moreau-Fauvarque C, Heitz-Marchaland C, et al. Role of transmembrane semaphoring Sema6A in oligodendrocyte differentiation and myelination. Glia. 2012;60(1):590–1604.
19.
Loria R, Bon G, Perotti V, et al. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget. 2015;6(5):2779–93.CrossRefPubMed
20.
Dhanabal M, Wu F, Alvarez E, et al. Recombinant semaphorin 6A‑1ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. Cancer Biol Ther. 2005;4:659–68.CrossRefPubMed
21.
Tran-Van H, Avota E, Börtlein C, et al. Measles virus modulates dendritic cell/T-cell communication at the level of plexinA1/neuropilin-1 recruitment and activity. Eur J Immunol. 2011;41:151–63.CrossRefPubMed
22.
Ueno K, Kumagai T, Kijima T, et al. Cloning and tissue expression of cDNAs from chromosome 5q21-22 which is frequently deleted in advanced lung cancer. Hum Genet. 1998;102:63–8.CrossRefPubMed
23.
Prislei S, Mozzetti S, Filippetti F, et al. From plasma membrane to cytoskeleton: a novel function for semaphorin 6A. Mol Cancer Ther. 2008;7(1):233–41.CrossRefPubMed
24.
Urbich C, Kaluza D, Frömel T, et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood. 2012;119:1607–16.CrossRefPubMed
25.
26.
Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71:435–78.CrossRefPubMed
27.
Parsons JT, Martin KH, Slack JK, et al. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000;19:5606–13.CrossRefPubMed
28.
Rutka JT, Muller M, Hubbard SL, et al. Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression. J Neuropathol Exp Neurol. 1999;58:198–209.CrossRefPubMed
29.
Natarajan M, Hecker TP, Gladson CL. FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer J. 2003;9:126–33.CrossRefPubMed
30.
Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Lett. 2009;273:1–14.CrossRefPubMed
Metadata
Title
SEMA6A is a prognostic biomarker in glioblastoma
Authors
Jiaxin Zhao
Haitao Tang
Hong Zhao
Wanli Che
Lei Zhang
Peng Liang
Publication date
01-11-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3584-y

Other articles of this Issue 11/2015

Tumor Biology 11/2015 Go to the issue

Research Article

Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

Research Article

MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway

Research Article

Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin

Research Article

Robo1 promotes angiogenesis in hepatocellular carcinoma through the Rho family of guanosine triphosphatases’ signaling pathway

Research Article

The pleiotropic effects of fisetin and hesperetin on human acute promyelocytic leukemia cells are mediated through apoptosis, cell cycle arrest, and alterations in signaling networks

Research Article

Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits